The oxidation of dopamine and epinine by the two forms of monoamine oxidase from rat liver. 1998

M Strolin Benedetti, and G Sanson, and L Bona, and M Gallina, and S Persiani, and K F Tipton
Department of Preclinical Development and Human Pharmacology, Zambon Group, Bresso, Italy.

Information on the "in vitro" oxidation of epinine by monoamine oxidase (MAO) compared to dopamine is very poor. The aim of this work was to study the oxidative deamination of epinine and dopamine by rat liver MAO-A and MAO-B. The contributions of MAO-A and B to the metabolism of dopamine (55% and 45%, respectively) and epinine (70% and 30%, respectively) were similar. The results of this study show that epinine is a substrate for both forms of MAO in rat liver, although the contribution of MAO A to the deamination of this secondary amine appears to be slightly more important than that of MAO B.

UI MeSH Term Description Entries
D007527 Isoenzymes Structurally related forms of an enzyme. Each isoenzyme has the same mechanism and classification, but differs in its chemical, physical, or immunological characteristics. Alloenzyme,Allozyme,Isoenzyme,Isozyme,Isozymes,Alloenzymes,Allozymes
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008297 Male Males
D008995 Monoamine Oxidase An enzyme that catalyzes the oxidative deamination of naturally occurring monoamines. It is a flavin-containing enzyme that is localized in mitochondrial membranes, whether in nerve terminals, the liver, or other organs. Monoamine oxidase is important in regulating the metabolic degradation of catecholamines and serotonin in neural or target tissues. Hepatic monoamine oxidase has a crucial defensive role in inactivating circulating monoamines or those, such as tyramine, that originate in the gut and are absorbed into the portal circulation. (From Goodman and Gilman's, The Pharmacological Basis of Therapeutics, 8th ed, p415) EC 1.4.3.4. Amine Oxidase (Flavin-Containing),MAO,MAO-A,MAO-B,Monoamine Oxidase A,Monoamine Oxidase B,Type A Monoamine Oxidase,Type B Monoamine Oxidase,Tyramine Oxidase,MAO A,MAO B,Oxidase, Monoamine,Oxidase, Tyramine
D010084 Oxidation-Reduction A chemical reaction in which an electron is transferred from one molecule to another. The electron-donating molecule is the reducing agent or reductant; the electron-accepting molecule is the oxidizing agent or oxidant. Reducing and oxidizing agents function as conjugate reductant-oxidant pairs or redox pairs (Lehninger, Principles of Biochemistry, 1982, p471). Redox,Oxidation Reduction
D003010 Clorgyline An antidepressive agent and monoamine oxidase inhibitor related to PARGYLINE. Clorgilin,Chlorgyline,Clorgiline
D003846 Deoxyepinephrine Sympathomimetic, vasoconstrictor agent. Deoxyadrenaline,Desoxyadrenaline,Methyldopamine,Desoxyepinephrine,Epinine
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

M Strolin Benedetti, and G Sanson, and L Bona, and M Gallina, and S Persiani, and K F Tipton
December 1981, Biochemical pharmacology,
M Strolin Benedetti, and G Sanson, and L Bona, and M Gallina, and S Persiani, and K F Tipton
January 1986, Neurochemistry international,
M Strolin Benedetti, and G Sanson, and L Bona, and M Gallina, and S Persiani, and K F Tipton
March 1975, Biochemical pharmacology,
M Strolin Benedetti, and G Sanson, and L Bona, and M Gallina, and S Persiani, and K F Tipton
October 1986, Biochemical pharmacology,
M Strolin Benedetti, and G Sanson, and L Bona, and M Gallina, and S Persiani, and K F Tipton
June 1983, Journal of neurochemistry,
M Strolin Benedetti, and G Sanson, and L Bona, and M Gallina, and S Persiani, and K F Tipton
December 1976, Biochemical pharmacology,
M Strolin Benedetti, and G Sanson, and L Bona, and M Gallina, and S Persiani, and K F Tipton
August 1985, Journal of neurochemistry,
M Strolin Benedetti, and G Sanson, and L Bona, and M Gallina, and S Persiani, and K F Tipton
September 1973, The Biochemical journal,
M Strolin Benedetti, and G Sanson, and L Bona, and M Gallina, and S Persiani, and K F Tipton
August 1969, Nature,
M Strolin Benedetti, and G Sanson, and L Bona, and M Gallina, and S Persiani, and K F Tipton
March 1980, Biochemical pharmacology,
Copied contents to your clipboard!